HPC · Science Deep Dive 2 April 2026 · revised 2026-04-02

Melatonin: What the Science Actually Shows About Sleep, Timing & Supplementation.

Melatonin is not a sedative. It is a timing signal, and the gap between how people use it and what controlled evidence supports is now a public health problem. Here is what the science actually says, and what to do with it.

Section: Bio · Sleep
Reading time: 22 min read
Sources: 44 · reviewed
Reviewed: Jun 2026

01The 1958 Discovery

Melatonin is a timing signal, not a sedative

In 1958, a dermatologist named Aaron Lerner spent four years grinding up 250,000 bovine pineal glands to isolate a single compound he believed would lighten skin pigment.[8] He was wrong about the skin. The molecule he extracted, melatonin, turned out to be something far more consequential: the chemical sentence the human body uses to tell itself what time it is. Nearly seven decades later, that sentence has become the best-selling supplement on American pharmacy shelves, taken nightly by millions of people who believe they are buying sleep.[8] Most of them are buying the wrong thing.

The numbers are worth sitting with. Between 1999 and 2018, US adult melatonin use quintupled, from 0.4% to 2.1% of the adult population, while high-dose use (above 5 mg per day) tripled.[1] By 2023, nearly one in five American children aged 10 to 13 were being given melatonin every month, with a median continuous use duration of 21 months, in a population for which no long-term paediatric safety data exists.[2] Poison control calls for unsupervised paediatric melatonin ingestion rose 530% between 2012 and 2021, from 8,337 to 52,563 cases, with gummy formulations accounting for 47% of exposures.[44][3]

The disconnect is not about whether melatonin works. It does. The disconnect is about what melatonin actually is. The controlled evidence, drawn from 44 peer-reviewed sources including Cochrane reviews, forced-desynchrony protocols, and the largest independent meta-analysis of melatonin for primary sleep disorders, converges on a conclusion most consumers would find surprising: melatonin is a mediocre hypnotic but a remarkably effective chronobiotic, a molecule whose primary clinical value is shifting the timing of the body's internal clock, not sedating the brain into unconsciousness.[22][26]

01 · The history

That reframe is not semantic. When you understand melatonin as a timing signal rather than a sedative, several problems with typical use become clear. The dose most people take is wrong: pharmacological doses of 3 to 10 mg overwhelm receptor sensitivity without improving sleep outcomes beyond what a physiological dose of 0.5 mg achieves.[27] The timing most people use is also wrong. Taking melatonin at bedtime places the dose in the wrong phase of the phase-response curve, producing mild sedation but no circadian advance.[39] And the environment most people sleep in actively destroys the signal they are trying to supplement: ordinary room light at 200 lux suppresses endogenous melatonin production by more than 50%.[15]

The result is a strange public health situation. Millions of people take a clock-setting hormone at the wrong time, in the wrong dose, in a light environment that simultaneously erases the signal they are trying to boost. And because melatonin is classified as a dietary supplement in the United States, exempt from the manufacturing controls applied to pharmaceuticals, 71% of over-the-counter products contain a dose that deviates by more than 10% from what the label claims, with some lots varying by up to 465%.[40]

This article traces what the science actually shows, from the molecular pathway that produces melatonin to the controlled human evidence that reveals its real clinical utility. The argument is not that melatonin is useless. The argument is that melatonin is misunderstood, and that understanding it correctly changes what you do with it.

02The Mechanism

The Signal Chain That Turns Darkness Into a Hormone

The story begins behind your eyes. A specialised class of retinal cells, intrinsically photosensitive retinal ganglion cells (ipRGCs) containing the photopigment melanopsin, detects ambient light intensity and transmits that signal directly to the brain's master clock via a process called photoentrainment.[16] These cells are not the ones you see with. They are the ones that tell your body whether it is day or night. Their peak sensitivity falls at 460 to 480 nanometres, the blue end of the visible spectrum, which is why short-wavelength light resets the circadian phase and suppresses melatonin approximately twice as powerfully as green light of the same intensity: a three-hour phase shift versus 1.5 hours in Lockley's controlled comparison.[16]

The signal travels via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), a cluster of approximately 20,000 neurons in the anterior hypothalamus that functions as the body's master pacemaker.[9][20] The SCN does not produce melatonin. It gates its production. During daylight hours, GABAergic inhibition from the SCN suppresses the sympathetic pathway that would otherwise activate the pineal gland.[20] When darkness arrives and that inhibition lifts, the sympathetic nervous system sends a noradrenergic signal to the pineal, activating the rate-limiting enzyme arylalkylamine N-acetyltransferase (AANAT) and initiating the conversion of serotonin into melatonin.[10]

The biosynthetic pathway is a four-step biochemical cascade: tryptophan → 5-HTP → serotonin → N-acetylserotonin (via AANAT) → melatonin (via HIOMT).[10] The entire process is light-gated. Any significant light exposure during the synthesis window qualifies as a disruptor. Gooley's controlled crossover in 116 subjects demonstrated that 200 lux of ordinary room light delays melatonin onset by approximately 1.5 hours and compresses the total duration of the biological night by 90 minutes.[15]

The retinohypothalamic relay from melanopsin-bearing ganglion cells through the suprachiasmatic nucleus to the pineal, and from the pineal into the bloodstream as a circulating clock signal.

Diagram · HPC

Once synthesised, melatonin broadcasts its timing signal through two G-protein-coupled receptor subtypes distributed across nearly every tissue in the body. MT1 receptors primarily regulate REM sleep architecture and acute melatonin signalling. MT2 receptors selectively promote non-REM sleep onset and mediate the circadian phase-shifting that represents melatonin's most clinically significant action.[11] Both receptor types couple through the inhibitory G-protein (Gi) to reduce intracellular cyclic AMP, creating a sleep-permissive state: a lowering of arousal threshold rather than a pharmacological knock-out.[11][12]

That distinction matters. A sedative like zolpidem forces sleep by amplifying GABA-A receptor activity. Melatonin does not force anything. It tells the body's peripheral clocks, in the liver, pancreas, immune system, and cardiovascular tissue, that night has arrived and that it is safe to shift into nocturnal metabolic programming.[9][18][19] Each of these organs contains its own autonomous clock gene network (CLOCK, BMAL1, PER, CRY), and the melatonin signal synchronises these peripheral oscillators to SCN time, a process called internal synchronisation.[9] When the signal is absent or mistimed, peripheral clocks drift, running on different schedules from each other and from the master pacemaker.

The critical timing marker is dim-light melatonin onset (DLMO), validated by Voultsios and colleagues as occurring approximately two hours before habitual sleep onset.[13] DLMO is the circadian system's version of a starting gun. It marks the moment the body begins its nightly transition from daytime catabolism to nighttime repair and immune surveillance. When melatonin supplementation is timed relative to DLMO rather than clock time, its phase-shifting potency increases substantially, a principle codified in Lewy's phase-response curve (PRC), which shows that evening doses advance the clock while morning doses delay it.[14]

03Evidence

The Five Strongest Studies on Melatonin, Timing & Sleep

01The claim

The single load-bearing finding

The hero study finds >50 % suppression.

Not all melatonin research is equal, and not all of it deserves equal weight in clinical decision-making. The field spans thousands of papers, from animal models and in vitro receptor studies to large-scale epidemiological cohorts and Cochrane systematic reviews. Ranking them requires a framework that distinguishes controlled experimental evidence from observational association, and methodological rigour from sample size alone. The five studies below are ranked using a 100-point rubric weighted across six criteria: study design architecture (30 points), sample adequacy (20), measurement rigou

Pooled estimate

>50

02How we measured

Grading the melatonin trials

Studies scored on design, sample, rigour, causality, replication.

For melatonin research, the critical methodological fault line is distinguishing sleep onset latency from genuine circadian phase advance, two outcomes that require different study designs and make most pooled meta-analyses harder to interpret than their headlines suggest.

Rubric weights

Design/35

Sample/20

Rigour/15

Causality/15

Replication/15

03The spread

Heterogeneity across 5 studies

Effect sizes across the ranked studies.

The gap between the independent meta-analytic estimate (−7.06 minutes) and the industry-sponsored Circadin trial (−24.3 minutes) deserves attention.[22][25] Wade and colleagues' 2007 study was funded by Neurim Pharmaceuticals, the company that manufactures and markets prolonged-release melatonin under the Circadin brand. Its effect size is more than three times larger than the independent pooled estimate. This does not prove the industry trial is wrong, since prolonged-release formulations may have genuinely different pharmacokinetics, bu

Spread

88 → 59 /100

Range of point estimates across ranked studies.

04What does not hold

Negative knowledge

What the evidence base does not support.

What the hierarchy reveals, taken as a whole, is a molecule whose reputation has outpaced its evidence for one application (sedation) while lagging behind its evidence for another (chronobiotic phase-shifting). The Cochrane jet lag data, the DLMO-confirmed DSPD trial, and the phase-response curve research all point in the same direction: melatonin's strength is in moving the clock, not in forcing sleep. Cruz-Sanabria's dose-response analysis adds the practical specification. 4 mg appears to be the ceiling for sleep effects, and timing three hours before bed outperforms the standard just-before

Consumer dose

The studies

5 trials. One pooled answer.

Below: the anchor study in full; then the forest plot at scale; then the supporting trials in ranked order.

01Anchor

, Exposure to Room Light before Bedtime Suppresses Melatonin Onset and Shortens Melatonin Duration in Humans

Gooley, Chamberlain & Smith Journal of Clinical Endocrinology & Metabolism 2011 Controlled Crossover · IV Plasma Sampling · N=116

Gooley's team placed 116 healthy volunteers in a controlled residential laboratory and measured plasma melatonin via continuous intravenous catheter sampling, the gold standard measurement method. The within-subjects crossover design compared standard room light (~200 lux) to dim light (<3 lux) acro

Rubric breakdown

Design27/35

Sample18/20

Rigour14/15

Causality15/15

Replication8/10

Citations6/10

Total 88/100

The strongest studies, ranked by methodological weight.

Each scored 0–100 against a six-criterion rubric, tagged by design and year; the anchor leads.

Anchor (Rank 1) Supporting

Rank Authors & title Journal · Year Finding Score

Sletten, Magee & Murray

, Efficacy of Melatonin with Behavioural Sleep-Wake Scheduling for Delayed Sleep-Wake Phase Disorder

PLOS Medicine · 2018

Low-dose melatonin (0.5 mg) advanced DLMO by 1.18 hours versus 0.26 hours for placebo (p < 0.001); wake time advanced by 34 minutes versus 5 minutes for placebo.[21]

84/100

Oda & Qawasmi

, Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders

PLOS ONE · 2013

Sleep onset latency reduced by a conservative estimate of 7.06 minutes (95% CI: −9.75, −4.37; fixed-effects primary analysis); total sleep time increased by 8.25 minutes; effects did not dissipate with continued use.[22]

79/100

Herxheimer

, Melatonin for the Prevention and Treatment of Jet Lag (Cochrane Review)

Cochrane Database of Systematic Reviews · 2002

Eight of ten randomised trials showed melatonin effective for jet lag when crossing five or more time zones; 0.5 to 5 mg doses equally effective; timing at destination bedtime (22:00–midnight local) was the critical variable.[23]

74/100

Sanabria, Bruno & Crippa

, Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug

Journal of Pineal Research · 2024

Dose-response modelling identified 4 mg as the optimal dose with a plateau above that threshold; administration 3 hours before bedtime significantly outperformed the standard 30-minute-before-bed protocol.[28]

59/100

04Stakes

The downstream cost of a disrupted melatonin signal across four biological systems

When the timing signal is absent or misaligned, the consequences extend far beyond poor sleep, into metabolism, cardiovascular function, immune regulation, and long-term disease risk.

01 System 01 · Metabolic

Cardiometabolic Disruption

In a small but highly controlled laboratory study (N=10), Scheer's forced desynchrony protocol demonstrated that circadian misalignment, independent of sleep loss, caused leptin to drop 17%, fasting glucose to rise 6% despite a 22% insulin increase, and mean arterial pressure to rise 3 mmHg.[29] These metabolic markers shifted within days, not months. Leproult's parallel RCT in men (N=26) confirmed that misalignment doubled insulin resistance markers and hsCRP inflammation versus aligned controls with identical total sleep time.[30]

10 These metabolic markers shifted within days, not months.

In practice

unexplained hunger despite adequate calories, afternoon energy crashes, elevated fasting glucose on routine labs

02 System 02 · Cardiovascular

Heart and Vascular Load

Morris and colleagues demonstrated that just three days of 12-hour behavioural inversion raised systolic blood pressure by 3.0 mmHg and diastolic by 1.5 mmHg in healthy adults.[31] In a small controlled study (N=20), Mason found that a single night of 100-lux bedroom light increased nighttime heart rate, decreased heart rate variability, and produced measurable next-morning insulin resistance.[32] Among those with the highest nighttime light exposure (top decile), Burns's observational UK Biobank analysis (N=88,905) found the risk of heart attack was associated with a 47% increase compared to those in the bottom half of exposure, though this was observational and does not establish causation.[5]

In practice

resting heart rate creeping upward, blood pressure readings trending above baseline, poor HRV scores

System 03 · Weight & Appetite

Adiposity and Hormonal Disruption

Park's prospective study of 43,722 women found that sleeping with artificial light (room light or television) was associated with 17% higher odds of gaining five or more kilograms over five years.[33] The mechanism is not caloric. It is hormonal. Scheer's forced misalignment data showed a 17% leptin reduction, meaning the satiety signal weakens when the circadian signal fails.[29] The body does not simply store more fat. It loses the hormonal brake that would normally prevent overconsumption.

43,722 The mechanism is not caloric. It is hormonal.

In practice

weight gain despite unchanged diet, persistent late-night appetite, difficulty maintaining body composition

04 System 04 · Long-Term Disease Risk

Cancer and Immune Dysregulation

Night shift work is classified as a Group 2A probable carcinogen by the IARC, with breast, prostate, colon, and rectal cancers implicated, a classification reflecting "strong" mechanistic evidence.[35] The specific epidemiology is less settled: Schernhammer's 2001 analysis of 78,562 nurses found that 30 or more years of rotating night shifts was associated with an RR of 1.36 for breast cancer (95% CI: 1.04–1.78), but a 2017 extended follow-up of the same cohort over 24 years found no significant association (HR = 0.95, 95% CI: 0.77–1.17).[34] The relationship between long-term night shift work and breast cancer risk remains an active area of investigation. Melatonin's antioxidant capacity, directly scavenging reactive oxygen species and upregulating SOD, catalase, and GPx, represents a plausible but not yet confirmed protective mechanism.[37] The nocturnal melatonin signal has been described as "the only circadian-driven anticancer signal identified in humans thus far."[4]

In practice

chronic immune suppression, slow wound healing, elevated inflammatory markers

05Protocol

A 4-Step Melatonin Signal Restoration Protocol

This protocol does not administer a sedative. It restores the light-darkness timing signal the suprachiasmatic nucleus requires to synchronise peripheral organ clocks and prevents modern artificial light from abolishing that signal before it can be generated.

01 Step 01 · Evening · 3–5h before bed

Time to Your DLMO

Take 0.5–1 mg immediate-release melatonin 3–5 hours before your target bedtime, not at bedtime. Estimate your DLMO as approximately 2 hours before the time you naturally feel drowsy on an unalarmed night.[39][21][28]

Why

The phase-response curve dictates that melatonin taken in the early biological evening advances the clock; melatonin taken at the sleep onset window produces sedation but no phase shift. Cruz-Sanabria's dose-response meta-analysis confirmed that 3 hours before bed significantly outperforms 30 minutes before bed.[28]

0.5–1 mg Take 0.5–1 mg immediate-release melatonin 3–5 hours before your target bedtime,

Common mistake

Taking melatonin at bedtime. This is the dominant misuse pattern globally. It places the dose in the wrong PRC phase, producing mild drowsiness but zero circadian advance.

02 Step 02 · Dusk onward

Dim Your Environment

Reduce all household lighting below ~10 lux in the 2–3 hours before target bedtime, candlelight level, not dimmer-switch level.[15][16]

Why

Gooley's controlled crossover showed that 200 lux suppresses melatonin by >50%. Total irradiance reduction is the primary variable; spectrum filtering is secondary. The goal is to stop suppressing endogenous production before you supplement exogenous production.

10 lux Reduce all household lighting below ~10 lux in the 2–3 hours before target bedti

Common mistake

Blue-light glasses without reducing total light intensity. Filtering wavelength while leaving brightness at 200 lux is a partial intervention that addresses the secondary variable while ignoring the primary one.

03 Step 03 · All 7 days

Fix Your Wake Time

Hold wake time within a 30–60 minute window across all seven days, including weekends.[29]

Why

Weekend sleep-ins of 2–3 hours restart circadian misalignment every Monday morning, creating chronic social jet lag, a measurable weekly phase disruption.[7] Scheer's forced desynchrony data shows that metabolic consequences appear within days of misalignment onset. The weekend-to-weekday phase shift is not benign recovery; it is iatrogenic disruption.

30–60 min Hold wake time within a 30–60 minute window across all seven days, including wee

Common mistake

Treating weekend late sleep as "recovery." The additional sleep hours do not offset the phase delay. They compound it by pushing the clock later and forcing a cold-start realignment every workweek.

04 Step 04 · Travel · ≥5 zones

Jet Lag Reset

On arrival night, take 0.5–5 mg melatonin at 22:00–midnight local destination time. Continue for 3–4 nights. Eastward travel shows the greatest benefit.[23][26]

Why

The Cochrane review confirmed this protocol across 10 RCTs. The critical variable is timing to destination clock, not departure clock. Jet lag's objectivity as a stressor makes this the cleanest application of melatonin's chronobiotic action.

0.5–5 mg On arrival night, take 0.5–5 mg melatonin at 22:00–midnight local destination ti

Common mistake

Taking melatonin on the flight at home-time bedtime, which delays rather than advances phase. Doses above 5 mg offer no additional phase-shift benefit and may cause next-day grogginess.

Operational logic

The protocol is deliberately simple because the evidence supports simplicity. The three highest-leverage variables are light exposure, melatonin timing, and wake-time consistency. Adding complexity, stacking supplements, cycling doses, using extended-release formulations, moves further from the controlled evidence base without demonstrated benefit. One caution on supplement quality: Erland and Saxena's analysis of 31 over-the-counter melatonin products found that 71% contained a dose deviating by more than 10% from the label claim, with lot-to-lot variability reaching 465% and 26% of products containing unlabelled serotonin.[40] Pharmaceutical-grade melatonin or USP-verified products eliminate this variability.

The operating principle is not optimisation. It is signal hygiene. The body already knows how to produce melatonin, synchronise peripheral clocks, and transition into nocturnal metabolic programming. The protocol's job is to stop interfering with that process. Where endogenous production is insufficient, through age-related decline, chronic light exposure, or phase disorders, the goal is to provide the minimum effective exogenous signal at the correct circadian phase.

06Verdict

The verdict.

Bottom line

Melatonin is not something you take. It is something your body makes, and the first question is whether you are letting it.

The reframe is not academic. It changes what you buy, when you take it, and what you do to your light environment in the hours before sleep. A 0.5 mg dose taken 3 to 5 hours before bed, in a room dimmed below 10 lux, aligns with the strongest controlled evidence. A 10 mg dose taken at midnight under full room lighting contradicts virtually everything the evidence hierarchy establishes. Both patterns are legal, widely practised, and sold on the same pharmacy shelf. The difference is not preference. It is physiology.

The whole argument, on one axis

Same molecule. Two sizes of effect.

01Claim

Clock signal, not sedative

The strongest controlled evidence establishes melatonin as a potent chronobiotic and a marginal hypnotic. Phase-shifting at physiological doses is robust and replicated; sedation at any dose is modest by independent meta-analytic estimate. The molecule's value is in its timing function, not its sedative side-effect.

02Consequence

Signal suppression compounds

Chronic melatonin signal disruption, from light exposure, mistiming, or age-related decline, produces cumulative metabolic, cardiovascular, and immunological costs that surface as clinical pathology over years. The body tolerates one bad night; it does not tolerate a permanently broken timing signal.

03Lever

Timing over dosing

The highest-leverage intervention is not a higher dose. It is the correct dose at the correct circadian phase in a dim environment, restoring the conditions under which the endogenous signal can function and the exogenous supplement can extend it.

07Bibliography

44 sources · ~6h est. corpus read · 44 visible

RCT · 1 Meta · 2 Review · 1 Journal · 36 Book · 4

Type

Sort

01 Journal

Li, J., Somers, V.K., Xu, H., Lopez-Jimenez, F., & Covassin, N2022

Trends in use of melatonin supplements among US adults, 1999–2018

JAMA327(5) · 1999–2018

doi: 10.1001/jama.2021.23652
02 Journal

Hartstein, L.E., Garrison, M.M., Lewin, D., Boergers, J., & LeBourgeois, M.K2023

Characteristics of melatonin use among US children and adolescents

JAMA Pediatrics177(12) · 1316–1317

doi: 10.1001/jamapediatrics.2023.4749
03 Journal

Freeman, D.I., Lind, J.N., Weidle, N.J., Geller, A.I., Stone, N.D., & Lovegrove, M.C2024

Notes from the field: emergency department visits for unsupervised pediatric melatonin ingestion, United States, 2019–2022

MMWR Morbidity and Mortality Weekly Report73(9) · 2019–2022
04 Journal

Lunn, R.M., Blask, D.E., Coogan, A.N., Figueiro, M.G., et al2017

Health consequences of electric lighting practices in the modern world

Science of the Total Environment607–608

doi: 10.1016/j.scitotenv.2017.07.056
05 Journal

Burns, A., Windred, D., et al2025

Nighttime light exposure and cardiovascular risk

JAMA Network Open

doi: 10.1001/jamanetworkopen.2024.40489
06 Book

Nobel Assembly at Karolinska Institutet2017

*The 2017 Nobel Prize in Physiology or Medicine, Press Release*. Nobel Assembly at Karolinska Institutet.

The 2017 Nobel Prize in Physiology or Medicine, Press Release
07 Journal

Rajaratnam, S.M. & Arendt, J2001

Health in a 24-h society

The Lancet358(9286) · 999–1005

doi: 10.1016/S0140-6736(01)06108-6
08 Journal

Chowdhury, I., Sengupta, A., & Maitra, S.K2008

Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human

Indian Journal of Biochemistry & Biophysics45(5) · 289–304
09 Journal

Zisapel, N2018

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation

British Journal of Pharmacology175(16) · 3190–3199

doi: 10.1111/bph.14116
10 Journal

Claustrat, B. & Leston, J2015

Melatonin: physiological effects in humans

Neurochirurgie61(2–3) · 2–3

doi: 10.1016/j.neuchi.2015.03.002
11 Review

Liu, J., Clough, S.J., Hutchinson, A.J., Adamah-Biassi, E.B., Popovska-Gorevski, M., & Dubocovich, M.L2016

MT1 and MT2 melatonin receptors: a therapeutic perspective

Annual Review of Pharmacology and Toxicology361–383

doi: 10.1146/annurev-pharmtox-010814-124742
12 Journal

Comai, S., Ochoa-Sanchez, R., & Gobbi, G2024

Melatonin, melatonin receptors and sleep: moving beyond traditional views

Journal of Pineal Research77(1)

doi: 10.1111/jpi.13011
13 Journal

Voultsios, A., Kennaway, D.J., & Dawson, D1997

Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin

Journal of Biological Rhythms12(5) · 457–466

doi: 10.1177/074873049701200507
14 Journal

Lewy, A.J., Ahmed, S., Jackson, J.M., & Sack, R.L1992

Melatonin shifts human circadian rhythms according to a phase-response curve

Chronobiology International9(5) · 380–392
15 Journal

Gooley, J.J., Chamberlain, K., Smith, K.A., Khalsa, S.B.S., Rajaratnam, S.M.W., Van Reen, E., Zeitzer, J.M., Czeisler, C.A., & Lockley, S.W2011

Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans

Journal of Clinical Endocrinology & Metabolism96(3) · 2010-2098

doi: 10.1210/jc.2010-2098
16 Journal

Lockley, S.W., Brainard, G.C., & Czeisler, C.A2003

High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light

Journal of Clinical Endocrinology & Metabolism88(9) · 4502–4505

doi: 10.1210/jc.2003-030570
17 Journal

West, K.E., Jablonski, M.R., Warfield, B., et al2011

Blue light from light-emitting diodes elicits a dose-dependent suppression of melatonin in humans

Journal of Applied Physiology110(3) · 619–626

doi: 10.1152/japplphysiol.01413.2009
18 Journal

Tordjman, S., Chokron, S., Delorme, R., et al2017

Melatonin: pharmacology, functions and therapeutic benefits

Current Neuropharmacology15(3) · 434–443

doi: 10.2174/1570159X14666161228122115
19 Journal

Brzezinski, A1997

Melatonin in humans

New England Journal of Medicine336(3) · 186–195

doi: 10.1056/NEJM199701163360306
20 Journal

Endotext2019

Physiology of the pineal gland and melatonin. In K.R. Feingold et al. (Eds.), *Endotext [Internet]*. MDText.com. NCBI Bookshelf, NBK550972.

Endotext [Internet]
21 RCT

Sletten, T.L., Magee, M., Murray, J.M., et al2018

Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: a double-blind, randomised clinical trial

PLOS Medicine15(6)

doi: 10.1371/journal.pmed.1002587
22 Journal

Ferracioli-Oda, E., Qawasmi, A., & Bloch, M.H2013

Meta-analysis: melatonin for the treatment of primary sleep disorders

PLOS ONE8(5)

doi: 10.1371/journal.pone.0063773
23 Meta

Herxheimer, A. & Petrie, K.J2002

Melatonin for the prevention and treatment of jet lag

Cochrane Database of Systematic Reviews2002(2)

doi: 10.1002/14651858.CD001520
24 Journal

Brzezinski, A., Vangel, M.G., Wurtman, R.J., et al2005

Effects of exogenous melatonin on sleep: a meta-analysis

Sleep Medicine Reviews9(1) · 41–50

doi: 10.1016/j.smrv.2004.06.004
25 Journal

Wade, A.G., Ford, I., Crawford, G., et al2007

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years

Current Medical Research and Opinion23(10) · 55–80

doi: 10.1185/030079907X233098
26 Journal

Arendt, J. & Skene, D.J2005

Melatonin as a chronobiotic

Sleep Medicine Reviews9(1) · 25–39

doi: 10.1016/j.smrv.2004.05.004
27 Journal

Sack, R.L., Hughes, R.J., Edgar, D.M., & Lewy, A.J1997

Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? *Sleep*, 20(10), 908–915.

Sleep20(10) · 908–915
28 Meta

Cruz-Sanabria, F., Bruno, S., Crippa, A., Frumento, P., Scarselli, M., Skene, D.J., & Faraguna, U2024

Optimizing the time and dose of melatonin as a sleep-promoting drug: systematic review of RCTs and dose-response meta-analysis

Journal of Pineal Research

doi: 10.1111/jpi.12985
29 Journal

Scheer, F.A.J.L., Hilton, M.F., Mantzoros, C.S., & Shea, S.A2009

Adverse metabolic and cardiovascular consequences of circadian misalignment

Proceedings of the National Academy of Sciences106(11) · 4453–4458

doi: 10.1073/pnas.0808180106
30 Journal

Leproult, R., Holmbäck, U., & Van Cauter, E2014

Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss

Diabetes63(6) · 1860–1869

doi: 10.2337/db13-1546
31 Journal

Morris, C.J., Purvis, T.E., Hu, K., & Scheer, F.A.J.L2016

Circadian misalignment increases cardiovascular disease risk factors in humans

Proceedings of the National Academy of Sciences113(10)

doi: 10.1073/pnas.1516953113
32 Journal

Mason, I.C., Grimaldi, D., Reid, K.J., et al2022

Light exposure during sleep impairs cardiometabolic function

Proceedings of the National Academy of Sciences119(12)

doi: 10.1073/pnas.2113290119
33 Journal

Park, Y.M., White, A.J., Jackson, C.L., Weinberg, C.R., & Sandler, D.P2019

Association of exposure to artificial light at night while sleeping with risk of obesity in women

JAMA Internal Medicine179(8) · 1061–1071

doi: 10.1001/jamainternmed.2019.0571
34 Journal

Schernhammer, E.S., Laden, F., Speizer, F.E., Willett, W.C., Hunter, D.J., Kawachi, I., & Colditz, G.A2001

Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study

Journal of the National Cancer Institute93(20) · 1563–1568

doi: 10.1093/jnci/93.20.1563
35 Journal

IARC Monographs Working Group2019

*Night Shift Work. IARC Monographs on the Identification of Carcinogenic Hazards to Humans*, Vol. 124. International Agency for Research on Cancer.

Night Shift Work. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
36 Journal

Wurtman, R.J2000

Age-related decreases in melatonin secretion, clinical consequences

Journal of Clinical Endocrinology & Metabolism85(6) · 2135–2136

doi: 10.1210/jcem.85.6.6660
37 Journal

Pandi-Perumal, S.R., BaHammam, A.S., Brown, G.M., Spence, D.W., Bharti, V.K., Kaur, C., Hardeland, R., & Cardinali, D.P2013

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

Neurotoxicity Research23(3) · 267–300

doi: 10.1007/s12640-012-9337-4
38 Journal

Chepesiuk, R2009

Missing the dark: health effects of light pollution

Environmental Health Perspectives117(1)

doi: 10.1289/ehp.117-a20
39 Journal

Lewy, A.J2010

Clinical implications of the melatonin phase response curve

Journal of Biological Rhythms25(5) · 319–324

doi: 10.1177/0748730410373877
40 Journal

Erland, L.A.E. & Saxena, P.K2017

Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content

Journal of Clinical Sleep Medicine13(2) · 275–281

doi: 10.5664/jcsm.6462
41 Book

Walker, M2017

*Why We Sleep: Unlocking the Power of Sleep and Dreams*. Scribner.

Why We Sleep: Unlocking the Power of Sleep and Dreams
42 Book

Sapolsky, R.M2004

*Why Zebras Don't Get Ulcers* (3rd ed.). Henry Holt and Company.

Why Zebras Don't Get Ulcers
43 Book

van der Kolk, B2014

*The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma*. Viking.

The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma
44 Journal

Lelak, K., Vohra, V., Neuman, M.I., Toce, M.S., & Sethuraman, U2022

Pediatric melatonin ingestions, United States, 2012–2021

MMWR Morbidity and Mortality Weekly Report71(22) · 2012–2021

Melatonin: What the Science Actually Shows About Sleep, Timing & Supplementation.

Melatonin is a timing signal, not a sedative

The Signal Chain That Turns Darkness Into a Hormone